Comparative canine pharmacokinetics-pharmacodynamics of fospropofol disodium injection, propofol emulsion, and cyclodextrin-enabled propofol solution following bolus parenteral administration

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3547-3552

  Mcintosh, Michelle P ^a   Rajewski, Roger A ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Cyclodextrin; Fospropofol; Mathematical model; Pain on injection; Pharmacodynamics; Pharmacokinetics; Prodrugs; Propofol

Indexed keywords

CYCLODEXTRIN ENABLED PROPOFOL; FOSPROPOFOL; PROPOFOL; PROPOFOL EMULSION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; MALE; NONHUMAN; POWER SPECTRUM; RANDOMIZED CONTROLLED TRIAL;

EID: 84864046276     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23195     Document Type: Article

References (35)

1. McGrane O, Hopkins G, Nielson A, Kang C. 2011. Procedural sedation with propofol: A retrospective review of the experiences of an emergency medicine residency program 2005 to 2010. [published online ahead of print, June 7, 2011] Am J Emerg Med. Accessed February 10, 2012.
2. Vanlersberghe C, Camu F. 2008. Propofol. Handb Exp Pharmacol 182:227-252.
3. Jalota L, Kalira V, George E, Shi YY, Hornuss C, Radke O, Pace NL, Apfel CC. 2011. Prevention of pain on injection of propofol: Systematic review and meta-analysis. BMJ 342:d1110.
4. Tan CH, Onsiong MK. 1998. Pain on injection of propofol. Anaesthesia 53(5):468-476.
5. White PF. 2002. Propofol formulation and pain on injection. Anesth Analg 94(4):1042.
6. McLeskey CH, Walawander CA, Nahrwold ML, Roizen MF, Stanley TH, Thisted RA, White PF, Apfelbaum JL, Grasela TH, Hug CC Jr. 1993. Adverse events in a multicenter phase IV study of propofol: Evaluation by anesthesiologists and postanesthesia care unit nurses. Anesth Analg 77(4 Suppl):S3-S9.
7. Trapani G, Latrofa A, Franco M, Lopedota A, Sanna E, Liso G. 1998. Inclusion complexation of propofol with 2-hydroxypropyl-beta-cyclodextrin. Physicochemical, nuclear magnetic resonance spectroscopic studies, and anesthetic properties in rat. trapani@ippo.uniba.it. J Pharm Sci 87(4):514-518.
8. Egan TD, Kern SE, Johnson KB, Pace NL. 2003. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): An electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 97(1):72-79.
9. Meadows J, Higgenbottom J. 2003. Formulations of propofol. Patent WO03017977.
10. Stella VJ. 2004. Prodrugs as therapeutics. Expert Opin Ther Patents 14:277-280.
11. Altomare C, Trapani G, Latrofa A, Serra M, Sanna E, Biggio G, Liso G. 2003. Highly water-soluble derivatives of the anesthetic agent propofol: In vitro and in vivo evaluation of cyclic amino acid esters. Eur J Pharm Sci 20(1):17-26.
12. Hendler S, Sanches R, Zielinski J. 2001. Water soluble pro-drugs of propofol. Patent US 6, 254, 853.
13. Garnock-Jones KP, Scott LJ. 2010. Fospropofol. Drugs 70(4):469-477.
14. Fechner J, Ihmsen H, Jeleazcov C, Schuettler J. 2009. Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2, 6-diisopropylphenol). Expert Opin Invest Drugs 18(10):1565-1571.
15. Welliver M, Rugari Susan M. 2009. New drug, fospropofol disodium: A propofol prodrug. AANA J 77(4):301-308.
16. Moore GD, Walker AM, MacLaren R. 2009. Fospropofol: A new sedative-hypnotic agent for monitored anesthesia care. Ann Pharmacother 43(11):1802-1808.
17. Struys MM, Fechner J, Schuttler J, Schwilden H. 2010. Requested retraction of six studies on the PK/PD and tolerability of fospropofol. Anesth Analg 110(4):1240.
18. Fechner J, Ihmsen H, Hatterscheid D, Jeleazcov C, Schiessl C, Vornov JJ, Schwilden H, Schuttler J. 2010. Retraction. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 112(4):1058.
19. Struys MM, Fechner J, Schuttler J, Schwilden H. 2010. Requested retraction of six studies on the PK/PD and tolerability of fospropofol. Eur J Anaesthesiol 27(4):395.
20. Wallentine CB, Shimode N, Egan TD, Pace NL. 2011. Propofol in a modified cyclodextrin formulation: First human study of dose-response with emphasis on injection pain. Anesth Analg 113(4):738-741.
21. Stella VJ, Zygmunt JJ, Georg IG, Safadi MS. Water-soluble prodrugs of hindered alcohols. Patent US6204257; US6451776; US6872838; US72447182000.
22. Plummer GF. 1987. Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. J Chromatogr 421(1):171-176.
23. Stanski DR. 1992. Pharmacodynamic modeling of anesthetic EEG drug effects. Annu Rev Pharmacol Toxicol 32:423-447.
24. Akaike H. 1974. A new look at the statistical model identification. Automatic Control, IEEE Transactions on 19(6):716-723.
25. Burnham KP, Anderson DR. 2002. Model selection and multimodel inference: A practical information-theoretic approach. Springer-Verlag.
26. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed., New York, NY: Marcel Dekker Inc.
27. Dutta S, Ebling WF. 1998. Formulation-dependent brain and lung distribution kinetics of propofol in rats. Anesthesiology 89(3):678-685.
28. Dutta S, Ebling WF. 1998. Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. J Pharm Pharmacol 50(1):37-42.
29. Doenicke AW, Roizen MF, Rau J, Kellermann W, Babl J. 1996. Reducing pain during propofol injection: The role of the solvent. Anesth Analg 82(3):472-474.
30. Doenicke AW, Roizen MF, Rau J, O'Connor M, Kugler J, Klotz U, Babl J. 1997. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 85(6):1399-1403.
31. Sim JY, Lee SH, Park DY, Jung JA, Ki KH, Lee DH, Noh GJ. 2009. Pain on injection with microemulsion propofol. Br J Clin Pharmacol 67(3):316-325.
32. Fechner J, Schwilden H, Schuettler J. 2008. Pharmacokinetics and pharmacodynamics of GPI 15715 or fospropofol (Aquavan injection)-A water-soluble propofol prodrug. Handb Exp Pharmacol 182:253-266.
33. Cockshott ID, Douglas EJ, Plummer GF, Simons PJ. 1992. The pharmacokinetics of propofol in laboratory animals. Xenobiotica 22(3):369-375.
34. Jamerson BD, Donn KH, Dukes GE, Messenheimer JA, Brouwer KL, Powell JR. 1990. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia 31(5):592-597.
35. Fischer JH, Patel TV, Fischer PA. 2003. Fosphenytoin: Clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 42(1):33-58.